Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2024-11-10 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
第五届董事会第十次会议决议的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement of the resolution passed at the company's fifth board of directors' tenth meeting. It specifically mentions the approval of a share repurchase plan and references compliance with relevant laws and stock exchange rules. The document does not contain detailed financial statements or comprehensive financial data but rather reports on a board decision regarding share buyback. It also refers to a separate announcement (number 2024-037) for more details on the share repurchase plan. Given the content focuses on a board meeting resolution about share repurchase, this fits best under the category of Transaction in Own Shares (POS). The document length is short and it is not a full report but an announcement of a board decision related to share repurchase.
2024-11-10 Chinese
关于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from 瑞康医药集团股份有限公司 regarding a share repurchase plan, including the purpose, amount, price, method, funding sources, implementation period, and related risks. It also includes information about management authorization and shareholder trading activities related to the repurchase. The document is lengthy (over 10,000 characters) and contains substantive details about the share buyback program, not just a brief notice or a link to a report. The content clearly focuses on the company's plan to repurchase its own shares and the specifics of this capital action. Therefore, this document fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares (share repurchase/issuance).
2024-11-10 Chinese
关于召开2024年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2024 second extraordinary general meeting of shareholders for 瑞康医药集团股份有限公司. It includes information about the meeting time, location, voting procedures (both onsite and online), eligibility to attend, agenda items, and proxy authorization forms. There is no financial data, earnings information, or audit content. The document is not a report itself but a formal announcement and invitation to shareholders to participate in the meeting and vote on proposals. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2024-10-30 Chinese
关于2024年前三季度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2024 first three quarters profit distribution plan of Rui Kang Pharmaceutical Group Co., Ltd. It includes details about the proposed cash dividend, the board and supervisory committee approvals, and the independent directors' opinions. The document does not contain full financial statements or comprehensive financial performance data but rather focuses on the profit distribution proposal and related approvals. The document length is 1812 characters, which is relatively short and typical for an announcement. It is not a full annual or interim report, nor is it a certification or regulatory compliance filing. The content fits the category of a Notice of Dividend Amount (DIV), as it announces the dividend amount, payment basis, and related shareholder meeting approvals for the dividend distribution.
2024-10-30 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "瑞康医药集团股份有限公司2024 年第三季度报告" which translates to "Ruikang Pharmaceutical Group Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and shareholder information for the third quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the period. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (13,308 characters) and the detailed financial content confirm it is the actual report, not just an announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-30 Chinese
第五届监事会第九次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolutions passed at the ninth meeting of the fifth Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It includes approval of the company's 2024 third quarter report and the 2024 first three quarters profit distribution plan. The document is short (826 characters) and primarily reports on the meeting decisions rather than containing the full financial report itself. It does not contain detailed financial statements or substantive financial data, but rather the approval of such reports and plans. Therefore, it is not the actual Interim/Quarterly Report (IR) but an announcement related to the meeting resolutions. This fits best under Regulatory Filings (RNS) as a general regulatory announcement about meeting resolutions and approvals.
2024-10-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.